GlobalData on MSN2d
Precision reports initial outcomes from Hepatitis B trial of PBGENE-HBV
The trial was tailored to evaluate the therapy at multiple ascending dose levels, with three dose administrations per level.
Hosted on MSN2mon
Precision gains CTA approval in Hong Kong for chronic hepatitis B therapy trial
in the ELIMINATE-B Phase I trial for curing chronic hepatitis B by targeting covalently closed circular DNA (cccDNA), the virus's replicative element. The company is currently recruiting subjects ...
Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate
Precision BioSciences, Inc. (NASDAQ:DTIL) revealed initial results from the first administration of PBGENE-HBV in cohort 1, ...
Nature2y
A precise platform for clinical gene editing
For its wholly owned in vivo programs, Precision is developing an ARCUS nuclease that targets chronic hepatitis B covalently closed circular DNA. For its primary hyperoxaluria type 1 program ...
Nature4y
Mutation detection and single-molecule counting using isothermal rolling-circle amplification
Using a single primer, RCA generates hundreds of tandemly linked copies of a covalently closed circle in a few ... We used two different pre-formed circular DNA templates for RCA signal coding ...
Business Wire4d
Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo g ...